Non-Hodgkin lymphomas and ionizing radiation: case report and review of the literature

Schmitz-Feuerhake, Inge; Frentzel‐Beyme, Rainer; Wolff, Roland

doi:10.1007/s00277-021-04729-z

Cited by 5 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is probably related to improvements in early detection and reflects an overall increasing trend in incidence of all cases of lymphoma. In fact, epidemiological studies show that the overall Hodgkin lymphoma incidence rate has been increasing for the past decade, especially among female, young and Asian populations (13) , and similar increasing trends have also been reported for non-Hodgkin lymphoma (14) .…”

Section: Discussionmentioning

confidence: 52%

Clinical and Pathological Characterization of Hepatic Lymphomas: A Retrospective Single-Center Study

Dias

Marques

Gonçalves

et al. 2023

Arq. Gastroenterol.

View full text Add to dashboard Cite

Background: The incidence of hepatic lymphoma has been increasing recently and diagnosis can be challenging as clinical presentation and radiological findings are usually variable and non-specific. Objective The aims of this study were to describe their main clinical, pathological and imaging characteristics and identify poor prognostic factors. Methods A retrospective study that included all patients with histological diagnosis of liver lymphoma over a 10-year period at our center was performed. Results A total of 36 patients were identified, with mean age of 56.6 years and male predominance (58%). There were three patients with primary liver lymphoma (8.3%) and 33 with secondary liver lymphoma (91.7%). The most common histological type was diffuse large B-cell lymphoma (33.3%). The most common clinical manifestations included fever, lymphadenopathy, weight loss, night sweats and abdominal discomfort; three patients (11.1%) were asymptomatic. Computed tomography scan revealed heterogenous radiological patterns including a single nodule (26.5%), multiple nodules (41.2%) or diffuse infiltration (32.4%). The mortality rate during follow-up was 55.6%. Higher levels of C-reactive protein (P=0.031) and absence of treatment response (P<0.001) were significantly associated with higher mortality. Conclusion Hepatic lymphoma is a rare disease that may involve liver as part of a systemic disease or, less commonly, be confined to this organ. Clinical presentation and radiological findings are often variable and non-specific. It is associated with high mortality and poor prognostic factors include higher levels of C-reactive protein and absence of response to treatment.

show abstract

Section: Discussionmentioning

confidence: 52%

Clinical and Pathological Characterization of Hepatic Lymphomas: A Retrospective Single-Center Study

Dias

Marques

Gonçalves

et al. 2023

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…ISS 1018 is in Phase II clinical trials for its synergistic effect with rituximab for the treatment of Non-Hodgkin’s lymphoma (NHL) [ 33 ]. NHL is a common cancer that begins in the lymphatic system and eventually spreads to other organs [ 116 ]. Rituximab has been extremely successful in treating many forms of NHL; however, there are still some forms that do not see any improvement following rituximab treatment.…”

Section: Rna Therapeuticsmentioning

confidence: 99%

Current Advances in RNA Therapeutics for Human Diseases

Zogg

Singh

2022

IJMS

102

View full text Add to dashboard Cite

Following the discovery of nucleic acids by Friedrich Miescher in 1868, DNA and RNA were recognized as the genetic code containing the necessary information for proper cell functioning. In the years following these discoveries, vast knowledge of the seemingly endless roles of RNA have become better understood. Additionally, many new types of RNAs were discovered that seemed to have no coding properties (non-coding RNAs), such as microRNAs (miRNAs). The discovery of these new RNAs created a new avenue for treating various human diseases. However, RNA is relatively unstable and is degraded fairly rapidly once administered; this has led to the development of novel delivery mechanisms, such as nanoparticles to increase stability as well as to prevent off-target effects of these molecules. Current advances in RNA-based therapies have substantial promise in treating and preventing many human diseases and disorders through fixing the pathology instead of merely treating the symptomology similarly to traditional therapeutics. Although many RNA therapeutics have made it to clinical trials, only a few have been FDA approved thus far. Additionally, the results of clinical trials for RNA therapeutics have been ambivalent to date, with some studies demonstrating potent efficacy, whereas others have limited effectiveness and/or toxicity. Momentum is building in the clinic for RNA therapeutics; future clinical care of human diseases will likely comprise promising RNA therapeutics. This review focuses on the current advances of RNA therapeutics and addresses current challenges with their development.

show abstract

Operator Lower Leg Radiation Dose during Fluoroscopically Guided Interventions is Effectively Reduced by Wearing Lead-Equivalent Leg Wraps

Ramanan

Pizano²,

Timaran³

et al. 2023

Annals of Vascular Surgery

View full text Add to dashboard Cite

Non-Hodgkin lymphomas and ionizing radiation: case report and review of the literature

Cited by 5 publications

References 39 publications

Clinical and Pathological Characterization of Hepatic Lymphomas: A Retrospective Single-Center Study

Clinical and Pathological Characterization of Hepatic Lymphomas: A Retrospective Single-Center Study

Current Advances in RNA Therapeutics for Human Diseases

Operator Lower Leg Radiation Dose during Fluoroscopically Guided Interventions is Effectively Reduced by Wearing Lead-Equivalent Leg Wraps

Contact Info

Product

Resources

About